<DOC>
	<DOCNO>NCT01124539</DOCNO>
	<brief_summary>The primary objective study determine 6-month Progression free survival ( PFS ) intravenous ( IV ) AR-67 administer adult confirm recurrence GBM recently ( &gt; 90 day ) recur treatment bevacizumab ( include patient 've receive temazolamide , bevacizumab ) . The primary objective rapid bevacizumab failure group ( &lt; 90 day ) determine 2-month PFS .</brief_summary>
	<brief_title>Study AR-67 Adult Patients With Recurrence Glioblastoma Multiforme ( GBM ) Gliosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>10-hydroxycamptothecin</mesh_term>
	<criteria>1 . Male female age 18 year old . 2 . Patient , legal representative , able provide studyspecific inform consent risk benefit treatment explain prior screen . 3 . Confined histopathology World Health Organization ( WHO ) Grade IV GBM Gliosarcoma primary diagnosis recurrence local pathology review . 4 . Unequivocal radiographic evidence recurrence tumor MRI within 14 day prior enrollment . 5 . Patients progress , surgery , measurable disease eligible long adequately recover surgery . 6 . Received prior radiotherapy temozolomide treatment . 7 . Received last chemotherapy biologic therapy treatment ≥14 day first dose study drug ( ≥42 day nitrosourea ≥90 day bevacizumab nonbevacizumab failure cohort therapeutic antibody administer ) , daily type regimen , ≥7 day 5 halflives drug ' pharmacokinetics/dynamics biologic activity , whichever longer , first dose study drug . For subject receive prior chemotherapy , toxicity need resolve ≤ Grade 1 prior administration study drug . For patient bevacizumab failure cohort , failure must occur within prior 90 day receive last bevacizumab dose . 8 . Completed radiotherapy ≥90 day study start . 9 . Completed administration investigational agent ≥14 day 5 halflives drug ' PK/dynamics biologic activity , whichever longer , study start . 10 . Karnofsky performance status ≥60 % . 11 . Recovered Grade 1 less toxic effect earlier intervention . 12 . Patients receive EIADs must switch nonEIADs least 14 day prior study start . 13 . Adequate renal , liver , bone marrow function accord follow criterion : Absolute neutrophil count ≥1500/mcL Platelets ≥150,000/mcL Total bilirubin within upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ≤ 2.5 X institutional ULN Creatinine within normal limit creatinine clearance ≥ 50 mL/min patient creatinine level normal limit . 14 . Demonstrated , opinion investigator , ability follow direction necessary participate clinical trial . 15 . Women childbearing potential must agree use acceptable contraceptive method follow : An intrauterine device document failure rate le 1 % per year . Vasectomized partner sterile prior female patient 's entry sole sexual partner female . Complete abstinence sexual intercourse 14 day exposure investigational product , dose period , least 21 day last dose investigational product . Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide , male condom diaphragm spermicide ) . Note : These method use consistently accordance product label instruction treat physician . Oral contraceptive reliable due potential drugdrug interaction use caution patient insist use contraceptive . 16 . A life expectancy great 2 month . 1 . Patients therapeutic Coumadin ; however , patient therapeutic Coumadin switch low molecular weight heparin ( LMWH ) least 7 day prior first dose eligible study participation . 2 . Female patient pregnant breastfeeding . 3 . Prior malignancy curatively treat basal cell cervical carcinoma situ adequately treat Stage I II cancer patient currently complete remission patient diseasefree three year . 4 . Uncontrolled concurrent illness include active infection require intravenous antibiotic , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 5 . Known HIV infection . 6 . Any condition would compromise treatment and/or evaluation reasonable safety . 7 . Completed intracranial surgery ≤ 14 day study start . 8 . Received antiepilpetic drug , CYP3A4 inducer ≤ 14 day prior screen study end . See Appendix 1 list enzyme induce antiepileptic drug . Inducers CYP3A4 may also alter metabolism AR67 . The following list CYP3A4 inducer prohibit 14 day prior screen discontinuation study : HIV : efavirenz , nevirapine Antibiotics : rifampin ( rifampicin ) , rifabutin , rifapentine Antiretrovirals : efavirenz , nevirapine Miscellaneous : St. John 's Wort , modafinil AntiEpileptic Drugs : phenytoin , phenobarbital , primidone , carbamazapine , oxcarbazapine topiramate 9 . Coadministration AR67 medication substrates CYP450 enzymes potential cause serious and/or lifethreatening AE 's prohibit . These medication include ( limited ) : Anticoagulants : therapeutic coumadin Oral hypoglycemics : glilpizide , glyburide , tolbutamide , glimepiride , nateglinice Erectile dysfunction agent : sildenafil , tadalafil , vardenafil Ergot derivative : dihydroergotamine , ergonovine , ergotamine , methylergonovine Neuroleptics : pimozide Antiarrhythmics : bepridil , flecainide , lidocaine , meziletine , amiodarone , quinidine , propafenone Immune modulators : cyclosporine , tacrolimus , sirolimus Miscellaneous : theophylline , quetiapine , risperidone , tacrine , clozapine , atomoxetine 10 . The following list CYP3A4 inhibitor prohibit 14 day prior screen discontinuation study : Antibiotics : clarithromycin , erythromycin , troleandomycin HIV : antiretrovirals ( delaviridine ) , protease inhibitor ( ritonavir , indinavir , saquinavir , nelfinavir , amprenavir , lopinavir ) Antifungals : itraconazole , ketoconazole , voriconazole , fluconazole ( &gt; 150 mg daily ) Antidepressants : nefazodone , fluvoxamine Calcium channel blocker : verapamil , diltiazem Gastrointestinal : cimetidine , aprepitant Miscellaneous : grapefruit juice 11 . Progressive disease topoisomerase I inhibitors . 12 . History anaphylactic injection reaction &gt; Grade 3 product use formulate AR67 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Adult Patients</keyword>
	<keyword>Recurrence Glioblastoma Multiforme</keyword>
	<keyword>Recurrence GBM</keyword>
	<keyword>Gliosarcoma</keyword>
</DOC>